Stefan Beyer joined Vibalogics in 2006 as Director of Corporate and Business Development, back when we were BioProtect Research. Not long after he became a part of the family, we were renamed Vibalogics, and Stefan was appointed CEO in early 2008, and then President in 2020.
Under Stefan’s leadership, Vibalogics has grown considerably, acquiring new clients across the globe. We have expanded from our home in Cuxhaven, Germany, with a new facility in Boxborough, MA, set to come online in late 2021 to provide late-phase clinical and commercial virotherapy support to international customers. Stefan has played a vital role in nurturing client relationships over the years, helping us build long-standing and loyal partnerships with customers that range from some of the world’s largest biopharma companies, to start-ups and university research teams.
Before his time with us, Stefan spent time at Scil Proteins as Business Development Management. He gained his PhD in 1996 and studied Microbiology, Biotechnology & Molecular Genetics at the University of Münster.